Search

Your search keyword '"Oliver Homann"' showing total 11 results
Start Over Author "Oliver Homann" Publisher american association for cancer research (aacr)
11 results on '"Oliver Homann"'

1. Supplementary File from AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer

Author

Paul E. Hughes, Julie M. Bailis, Angela Coxon, Jude Canon, Pedro J. Beltran, Jennitte Stevens, Sean Caenepeel, Yajing Yang, Tobias Raum, Joshua T. Pearson, Matthias Friedrich, Oliver Homann, Fei Lee, Siyuan Liu, Jonathan Werner, Christopher M. Murawsky, Melissa Thomas, Petra Deegen, Jinghui Zhan, Juan Estrada, Edward K. Lobenhofer, Keegan Cooke, and Michael J. Giffin

Abstract

Tissue expression datasets

Published
2023

2. Supplementary Methods from AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer

Author

Paul E. Hughes, Julie M. Bailis, Angela Coxon, Jude Canon, Pedro J. Beltran, Jennitte Stevens, Sean Caenepeel, Yajing Yang, Tobias Raum, Joshua T. Pearson, Matthias Friedrich, Oliver Homann, Fei Lee, Siyuan Liu, Jonathan Werner, Christopher M. Murawsky, Melissa Thomas, Petra Deegen, Jinghui Zhan, Juan Estrada, Edward K. Lobenhofer, Keegan Cooke, and Michael J. Giffin

Abstract

File contains Supplementary Methods

Published
2023

3. Supplementary Figure 3 from AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer

Author

Paul E. Hughes, Julie M. Bailis, Angela Coxon, Jude Canon, Pedro J. Beltran, Jennitte Stevens, Sean Caenepeel, Yajing Yang, Tobias Raum, Joshua T. Pearson, Matthias Friedrich, Oliver Homann, Fei Lee, Siyuan Liu, Jonathan Werner, Christopher M. Murawsky, Melissa Thomas, Petra Deegen, Jinghui Zhan, Juan Estrada, Edward K. Lobenhofer, Keegan Cooke, and Michael J. Giffin

Abstract

Supplementary Figure 3 Evaluation of DLL3 expression in tumor types other than SCLC.

Published
2023

4. Supplementary Figure 6 from AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer

Author

Paul E. Hughes, Julie M. Bailis, Angela Coxon, Jude Canon, Pedro J. Beltran, Jennitte Stevens, Sean Caenepeel, Yajing Yang, Tobias Raum, Joshua T. Pearson, Matthias Friedrich, Oliver Homann, Fei Lee, Siyuan Liu, Jonathan Werner, Christopher M. Murawsky, Melissa Thomas, Petra Deegen, Jinghui Zhan, Juan Estrada, Edward K. Lobenhofer, Keegan Cooke, and Michael J. Giffin

Abstract

Supplementary Figure 6 A, Expression of human CD25, CD69, PD-1, and 4-1BB on human CD4+ T cells isolated from mouse lungs harboring SHP-77 tumors 168 hours after treatment with AMG 757 or a control HLE BiTE® molecule. B, Expression of human CD25, CD69, PD-1, and 4-1BB on human CD8+ T cells isolated from mouse lungs harboring SHP-77 tumors 168 hours after treatment with either AMG 757 or a control HLE BiTE® molecule. *P < 0.05; **P < 0.01; *** P< 0.001

Published
2023

5. Data from AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer

Author

Paul E. Hughes, Julie M. Bailis, Angela Coxon, Jude Canon, Pedro J. Beltran, Jennitte Stevens, Sean Caenepeel, Yajing Yang, Tobias Raum, Joshua T. Pearson, Matthias Friedrich, Oliver Homann, Fei Lee, Siyuan Liu, Jonathan Werner, Christopher M. Murawsky, Melissa Thomas, Petra Deegen, Jinghui Zhan, Juan Estrada, Edward K. Lobenhofer, Keegan Cooke, and Michael J. Giffin

Abstract

Purpose:Small-cell lung cancer (SCLC) is an aggressive neuroendocrine tumor with a high relapse rate, limited therapeutic options, and poor prognosis. We investigated the antitumor activity of AMG 757, a half-life extended bispecific T-cell engager molecule targeting delta-like ligand 3 (DLL3)—a target that is selectively expressed in SCLC tumors, but with minimal normal tissue expression.Experimental Design:AMG 757 efficacy was evaluated in SCLC cell lines and in orthotopic and patient-derived xenograft (PDX) mouse SCLC models. Following AMG 757 administration, changes in tumor volume, pharmacodynamic changes in tumor-infiltrating T cells (TILs), and the spatial relationship between the appearance of TILs and tumor histology were examined. Tolerability was assessed in nonhuman primates (NHPs).Results:AMG 757 showed potent and specific killing of even those SCLC cell lines with very low DLL3 expression (Conclusions:AMG 757 has a compelling safety and efficacy profile in preclinical studies making it a viable option for targeting DLL3-expressing SCLC tumors in the clinical setting.

Published
2023

6. Supplementary Tables from AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer

Author

Paul E. Hughes, Julie M. Bailis, Angela Coxon, Jude Canon, Pedro J. Beltran, Jennitte Stevens, Sean Caenepeel, Yajing Yang, Tobias Raum, Joshua T. Pearson, Matthias Friedrich, Oliver Homann, Fei Lee, Siyuan Liu, Jonathan Werner, Christopher M. Murawsky, Melissa Thomas, Petra Deegen, Jinghui Zhan, Juan Estrada, Edward K. Lobenhofer, Keegan Cooke, and Michael J. Giffin

Abstract

This file contains Supplementary Tables 1-5

Published
2023

7. Supplementary Figure 1 from AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer

Author

Paul E. Hughes, Julie M. Bailis, Angela Coxon, Jude Canon, Pedro J. Beltran, Jennitte Stevens, Sean Caenepeel, Yajing Yang, Tobias Raum, Joshua T. Pearson, Matthias Friedrich, Oliver Homann, Fei Lee, Siyuan Liu, Jonathan Werner, Christopher M. Murawsky, Melissa Thomas, Petra Deegen, Jinghui Zhan, Juan Estrada, Edward K. Lobenhofer, Keegan Cooke, and Michael J. Giffin

Abstract

Supplementary Figure 1 DLL3 is differentially expressed in SCLC tumors and cell lines compared with normal tissues.

Published
2023

8. Supplementary Figure 2 from AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer

Author

Paul E. Hughes, Julie M. Bailis, Angela Coxon, Jude Canon, Pedro J. Beltran, Jennitte Stevens, Sean Caenepeel, Yajing Yang, Tobias Raum, Joshua T. Pearson, Matthias Friedrich, Oliver Homann, Fei Lee, Siyuan Liu, Jonathan Werner, Christopher M. Murawsky, Melissa Thomas, Petra Deegen, Jinghui Zhan, Juan Estrada, Edward K. Lobenhofer, Keegan Cooke, and Michael J. Giffin

Abstract

Supplementary Figure 2 Representative photomicrographs of DLL3 immunostaining (brown color) in normal human tissues using immunohistochemistry.

Published
2023

9. Supplementary Figure 5 from AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer

Author

Paul E. Hughes, Julie M. Bailis, Angela Coxon, Jude Canon, Pedro J. Beltran, Jennitte Stevens, Sean Caenepeel, Yajing Yang, Tobias Raum, Joshua T. Pearson, Matthias Friedrich, Oliver Homann, Fei Lee, Siyuan Liu, Jonathan Werner, Christopher M. Murawsky, Melissa Thomas, Petra Deegen, Jinghui Zhan, Juan Estrada, Edward K. Lobenhofer, Keegan Cooke, and Michael J. Giffin

Abstract

Supplementary Figure 5 A, DLL3 RNA expression levels in a panel of SCLC patient-derived xenograft (PDX) models compared with positive (NCI-H82) and negative (NCI-H460) control SCLC cell lines. Data are reported as relative quantification normalized to NCI-H460 cell line expression. B, DLL3 protein expression levels in a panel of SCLC PDX models compared with positive (NCI-H82) and negative (NCI-H460) control SCLC cell lines. GAPDH, glyceraldehyde 3-phosphate dehydrogenase.

Published
2023

10. Supplementary Figure 4 from AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer

Author

Paul E. Hughes, Julie M. Bailis, Angela Coxon, Jude Canon, Pedro J. Beltran, Jennitte Stevens, Sean Caenepeel, Yajing Yang, Tobias Raum, Joshua T. Pearson, Matthias Friedrich, Oliver Homann, Fei Lee, Siyuan Liu, Jonathan Werner, Christopher M. Murawsky, Melissa Thomas, Petra Deegen, Jinghui Zhan, Juan Estrada, Edward K. Lobenhofer, Keegan Cooke, and Michael J. Giffin

Abstract

Supplementary FIgure 4 AMG 757 demonstrated antitumor activity in the WM266-4 melanoma xenograft model.

Published
2023

11. AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer

Author

Jinghui Zhan, Christopher Murawsky, Petra Deegen, Jonathan Werner, Oliver Homann, Siyuan Liu, Melissa Thomas, Angela Coxon, Keegan Cooke, Pedro J. Beltran, Joshua T. Pearson, Juan Estrada, Fei Lee, Tobias Raum, Julie M. Bailis, Matthias Friedrich, Jude Canon, Jennitte Stevens, Giffin Michael John, Sean Caenepeel, Yajing Yang, Paul E. Hughes, and Edward K. Lobenhofer

Subjects
0301 basic medicine, Cancer Research, Lung Neoplasms, T-Lymphocytes, T cell, Antineoplastic Agents, Apoptosis, Mice, SCID, Mice, 03 medical and health sciences, 0302 clinical medicine, Mice, Inbred NOD, Antibodies, Bispecific, Tumor Cells, Cultured, Animals, Humans, Medicine, Potency, Lung cancer, Cell Proliferation, business.industry, Intracellular Signaling Peptides and Proteins, Antibodies, Monoclonal, Membrane Proteins, Half-life, medicine.disease, Small Cell Lung Carcinoma, Xenograft Model Antitumor Assays, respiratory tract diseases, Gene Expression Regulation, Neoplastic, 030104 developmental biology, medicine.anatomical_structure, Oncology, Tolerability, Cell culture, 030220 oncology & carcinogenesis, Pharmacodynamics, Cancer research, Female, Non small cell, business
Abstract

Purpose: Small-cell lung cancer (SCLC) is an aggressive neuroendocrine tumor with a high relapse rate, limited therapeutic options, and poor prognosis. We investigated the antitumor activity of AMG 757, a half-life extended bispecific T-cell engager molecule targeting delta-like ligand 3 (DLL3)—a target that is selectively expressed in SCLC tumors, but with minimal normal tissue expression. Experimental Design: AMG 757 efficacy was evaluated in SCLC cell lines and in orthotopic and patient-derived xenograft (PDX) mouse SCLC models. Following AMG 757 administration, changes in tumor volume, pharmacodynamic changes in tumor-infiltrating T cells (TILs), and the spatial relationship between the appearance of TILs and tumor histology were examined. Tolerability was assessed in nonhuman primates (NHPs). Results: AMG 757 showed potent and specific killing of even those SCLC cell lines with very low DLL3 expression ( Conclusions: AMG 757 has a compelling safety and efficacy profile in preclinical studies making it a viable option for targeting DLL3-expressing SCLC tumors in the clinical setting.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results